117 related articles for article (PubMed ID: 22998476)
1. Treatment of BRAF inhibitor-induced hyperkeratosis.
Battley JE; Lenihan E; Redmond HP; Murphy M; Power DG
Acta Oncol; 2013 May; 52(4):874-7. PubMed ID: 22998476
[No Abstract] [Full Text] [Related]
2. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
3. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
4. RASopathic alopecia: hair changes associated with vemurafenib therapy.
Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
[No Abstract] [Full Text] [Related]
5. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
6. Overcoming metastatic melanoma with BRAF inhibitors.
Hong S; Hong S; Han SB
Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
[TBL] [Abstract][Full Text] [Related]
7. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.
Wilgenhof S; Neyns B
J Clin Oncol; 2015 Oct; 33(28):e109-11. PubMed ID: 24733801
[No Abstract] [Full Text] [Related]
8. BRAF inhibitor activity in V600R metastatic melanoma--response.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 May; 49(7):1797-8. PubMed ID: 23490649
[No Abstract] [Full Text] [Related]
9. [Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Heneberg P
Klin Onkol; 2012; 25(5):333-9. PubMed ID: 23102194
[TBL] [Abstract][Full Text] [Related]
10. [BRAF inhibitor and MEK inhibitor].
Uhara H
Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
[No Abstract] [Full Text] [Related]
11. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Amaravadi RK; Hamilton KE; Ma X; Piao S; Portillo AD; Nathanson KL; Carlino MS; Long GV; Puzanov I; Xu X; Morrissette JJ; Tsai KY; Flaherty KT; Sosman JA; Goodman GR; McArthur GA; Rustgi AK; Metz DC; Schuchter LM; Chapman PB; Sepulveda AR
Clin Cancer Res; 2015 Dec; 21(23):5215-21. PubMed ID: 26202952
[TBL] [Abstract][Full Text] [Related]
12. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.
Satzger I; Degen A; Asper H; Kapp A; Hauschild A; Gutzmer R
J Clin Oncol; 2013 May; 31(13):e220-2. PubMed ID: 23530102
[No Abstract] [Full Text] [Related]
13. Dabrafenib in the treatment of metastatic or unresectable melanoma.
Khoja L; Hogg D
Expert Rev Anticancer Ther; 2015 Mar; 15(3):265-76. PubMed ID: 25711514
[TBL] [Abstract][Full Text] [Related]
14. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
[TBL] [Abstract][Full Text] [Related]
15. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors.
Falchook GS; Rady P; Konopinski JC; Busaidy N; Hess K; Hymes S; Nguyen HP; Prieto VG; Bustinza-Linares E; Lin Q; Parkhurst KL; Hong DS; Sherman S; Tyring SK; Kurzrock R
Arch Dermatol Res; 2016 Jul; 308(5):357-65. PubMed ID: 27098388
[TBL] [Abstract][Full Text] [Related]
16. Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors.
Reinhard R; Gebhardt C; Schmieder A; Umansky V; Utikal J
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e375-e377. PubMed ID: 28222227
[No Abstract] [Full Text] [Related]
17. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
[TBL] [Abstract][Full Text] [Related]
18. Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.
Erfan G; Puig S; Carrera C; Arance A; Gaba L; Victoria I; Garcia-Herrera A; Alos L; Malvehy J
Acta Derm Venereol; 2017 Feb; 97(2):258-260. PubMed ID: 27353949
[No Abstract] [Full Text] [Related]
19. Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib.
Lilly E; Burke M; Kluger H; Choi J
JAMA Dermatol; 2015 Jan; 151(1):102-3. PubMed ID: 25250477
[No Abstract] [Full Text] [Related]
20. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M
Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690
[No Abstract] [Full Text] [Related]
[Next] [New Search]
